The Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a)
Status:
Unknown status
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
Lipoprotein (a) [Lp (a)] is an independent cardiovascular risk (CVR) both in the general
population and in patients with type 2 diabetes mellitus (DM-2). Until now no effective
treatment is known to decrease the levels of Lp (a) levels and thus achieve a reduction of
CVR. Among the new antidiabetic drugs are GLP-1Receptor agonists(GLP-1R). In addition to
lowering blood glucose, these drugs have other beneficial effects. In our laboratory we have
demonstrated that both native GLP-1 and various GLP-1R agonsits reduce the synthesis of Lp
(a) in hepatocytes. The objective of the study is to test in humans the results observed in
vitro. We will analyze whether treatment with GLP-1R agonists (Liraglutide, Exenatide or
Lixisenatida) will reduce serum levels of Lp (a) in patients with DM-2.
Phase:
Phase 4
Details
Lead Sponsor:
Hospital Universitari Vall d'Hebron Research Institute